Depatuxizumab Mafodotin

Summary

Depatuxizumab Mafodotin (CHEMBL3707277) is a phase-3 clinical-stage antibody drug conjugate; indicated across 4 conditions including glioblastoma and gliosarcoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• Indications: 4 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707277
Name	Depatuxizumab Mafodotin
Type	Antibody drug conjugate
Max phase	3

Also known as: Abt-414, ABT-414, Depatuxizumab mafodotin, Depatuxizumab mafodotina, Depatuxizumab mafodotine, DEPATUXIZUMAB MAFODOTIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glioblastoma	3	MONDO:0018177	EFO:0000519
gliosarcoma	3	MONDO:0016681	EFO:1001465
neoplasm	1	MONDO:0005070	EFO:0000616
glioma	1	MONDO:0021042	MONDO:0100342

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1	2
PHASE2	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02573324	PHASE3	COMPLETED	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
NCT03419403	PHASE3	TERMINATED	UNITE Study: Understanding New Interventions With GBM ThErapy
NCT02343406	PHASE2	COMPLETED	Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
NCT02590263	PHASE1/PHASE2	COMPLETED	Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
NCT01741727	PHASE1	COMPLETED	A Study of ABT-414 in Subjects With Solid Tumors
NCT01800695	PHASE1	COMPLETED	Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
NCT03123952	Not specified	NO_LONGER_AVAILABLE	Expanded Access to ABT-414

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).